Replies to post #32166 on RespireRx Pharmaceuticals Inc (RSPI)

[atheroprevent]

Good points, Enemem. The RD/SA overlap will also be an area of greater interest to BP, as well.

Trying to stay grounded, but a positive result in SA will result in data that would be widely published. The only pharmacologic treatment showing SA benefit so far has been a small study in a yet to be approved weight loss drug. >10% weight reduction did improve oxygen desaturation and number of apnea/hypopnea events. The road, however, to FDA approving a weight loss drug is paved with potholes, much like trying to move an ADHD drug forward.